COMPASS Pathways (“COMPASS Pathways” or the “Company”) (NASDAQ: CMPS) is a clinical stage mental healthcare company pioneering the development of psilocybin therapy, with an initial focus on TRD, a subset of MDD, comprising 100M patients who are inadequately served two or more antidepressant treatments.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
